At Advicenne, we are committed to innovating in the areas of formulation and clinical development. Tasteless and easy to administer, ADV7103 will be commercialized in small-size formats that offer flexible, personalized dosing – because pathbreaking treatments for rare diseases should be available to patients of all ages.Headquartered in Nîmes, France, Advicenne was listed on the Euronext Paris stock exchange in December 20...
At Advicenne, we are committed to innovating in the areas of formulation and clinical development. Tasteless and easy to administer, ADV7103 will be commercialized in small-size formats that offer flexible, personalized dosing – because pathbreaking treatments for rare diseases should be available to patients of all ages.Headquartered in Nîmes, France, Advicenne was listed on the Euronext Paris stock exchange in December 2017
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.